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Abstract
Summary Pharmacologic therapy is recommended to reduce
future fracture risk. We examined osteoporosis medications
dispensed to older women after first fracture. Only 23 % re-
ceived therapy during the first year post-fracture. Prior osteo-
porosis therapy, a prior osteoporosis diagnosis, and older age
were good predictors of post-fracture osteoporosis therapy.
Introduction Pharmacologic therapy is recommended after
osteoporotic fracture to reduce future fracture risk. The objec-
tive of this retrospective study was to examine osteoporosis
therapy dispensed to women post-fracture.
Methods We identified women ≥50 years old in a large ad-
ministrative claims database from 2003 to mid-2012 who
were continuously enrolled 2 years before (baseline) and
1 year after first osteoporotic fracture. Exclusions were Paget’s
disease or malignant neoplasm. Pre- and post-fracture osteo-
porosis therapies (oral and parenteral) were assessed overall
and by fracture site.
Results A total of 47,171 women of mean (SD) age of 63 (10)
years were eligible; fractures included 8 % hip, 17 % verte-
bral, 73 % non-hip/non-vertebral, and 3 % multiple fracture
sites. Only 18% received osteoporosis therapy within 90 days
and 23%within 1 year post-fracture. Overall, 19% of women
had a prior osteoporosis diagnosis; 20 % had received osteo-
porosis therapy during baseline. Of 37,649 (80 %) women
without baseline therapy, only 9 % initiated pharmacologic
therapy within 1 year. The adjusted odds ratio (OR) of therapy
within 1 year post-fracture was significantly greater for wom-
en who had received baseline osteoporosis therapy (versus
none) and who had vertebral (OR 12.7, 95 % confidence
interval (CI) 11.2–14.5), hip (15.2, 12.5–18.7), or non-hip/
non-vertebral fracture (34.4, 31.7–37.3). Other significant
predictors included pre-fracture osteoporosis diagnosis (1.6,
1.4–1.7) and older age (OR range, 1.3–1.7). Treatment adher-
ence was significantly better among women with baseline
osteoporosis diagnosis.
Conclusions The substantial post-fracture treatment gap rep-
resents an important unmet need for women with osteoporotic
fractures. Fracture liaison or adherence programs could lead to
improved post-fracture treatment rates.
Keywords Hip fracture . Osteoporosis . Post-fracture
therapy . Under-treatment . Vertebral fracture
Introduction
The burden on patients and health care systems associated
with osteoporotic fractures is substantial and likely to remain
so for the foreseeable future due to the aging worldwide
population [1–3]. In the USA, the prevalence of osteoporosis
at either the lumbar spine or femoral neck among women
50 years of age and older has been estimated at 17%, affecting
seven million women; one in two women is projected to
experience an osteoporotic fracture during her lifetime [4, 5].
The occurrence of osteoporotic fractures is well established
as an important risk factor for future fractures [6–11]. In the
USA, the National Osteoporosis Foundation guidelines
Electronic supplementary material The online version of this article
(doi:10.1007/s00198-014-2827-x) contains supplementary material,
which is available to authorized users.
A. Wilk
Department of Biostatistics, Virginia Commonwealth University,
Richmond, VA, USA
S. Sajjan :A. Modi (*) : P. Mavros
Center for Observational and Real-World Evidence, Merck & Co.,




AsclepiusJT LLC, New York, NY, USA
Osteoporos Int (2014) 25:2777–2786
DOI 10.1007/s00198-014-2827-x
recommend consideration of pharmacotherapy after hip or
vertebral fracture in post-menopausal women and men
50 years of age and older [5]. Several pharmacologic therapies
have proven efficacy for reducing risk of osteoporotic fracture
[12, 13]; however, women and men at risk of fracture often do
not receive preventive treatment [14, 15]. In many countries,
the post-fracture care gap is a problem, as patients with hip or
other fractures are often not prescribed osteoporosis therapy
[15–20]. Moreover, poor adherence and lack of persistence
with therapy are common even among patients who are pre-
scribed with osteoporosis therapy [21, 22].
The objective of this retrospective study was to examine
osteoporosis therapy dispensed to women post-fracture. We
sought to describe patient demographic and clinical character-
istics and osteoporosis treatment status, including medication
use and adherence, prior to first osteoporotic fracture and
within 90 days and 1 year post-fracture for women in a large
managed care population in the USA. In addition, we aimed to
assess predictors of post-fracture medication use within 1 year
post-fracture.
Methods
Data source and study population
We used de-identified, longitudinal patient information
contained in the i3 Invision Datamart database (now known
as the Clinformatics™ Data Mart [23]). This administrative
claims dataset contains medical and pharmacy claims and
laboratory results for a large geographically diverse patient
population in the USA including approximately three million
patients with osteoporosis. Available data included patient
enrollment and administrative claims data for outpatient visits,
hospitalizations, laboratory tests, and pharmacy claims. Dis-
ease diagnoses and comorbidities were identified in the
dataset using the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis
codes [24]. Medications were identified using the National
Drug Code Directory (NDC) codes in the pharmacy claims
[25] and J-codes for intravenous drugs in the medical claims.
We studied women 50 years of age and older who experi-
enced their first osteoporotic fracture between January 1, 2005
and June 30, 2011. To be eligible, women had to be continu-
ously enrolled in the database for at least 2 years prior to
(baseline period) and at least 1 year post-fracture; the date of
first recorded (index) fracture was defined as the index date.
Thus, the entire study window was from January 1, 2003 to
June 30, 2012.
Osteoporotic fractures were identified by ICD-9-CM diag-
nosis codes [24, 26] and categorized by site into four groups:
vertebral fracture only, hip fracture only, non-hip/non-verte-
bral, and fractures at multiple sites.
We excluded patients with a record of fracture before the
index date, a diagnosis of Paget’s disease (osteitis deformans;
ICD-9-CM code 731.0) at any time in the database, or a
diagnosis of malignant neoplasm (ICD-9-CM codes 140.xx
to 208.xx, 230.xx to 239.xx, or 172.xx) during their 3-year
study period.
Study baseline characteristics
We assessed patients’ age at the index date, insurance type, the
presence or absence of 28 comorbidities (listed in the Online
Resource Table S1), and the Charlson comorbidity index
score to quantify overall comorbidity [27]. In addition, for
the baseline period, we assessed the presence of bone mineral
density tests (CPTcodes 76070–76071, 76075–76076, 76078,
76977, and 77078–77083), the history of falls resulting in
medical services (ICD-9-CM codes E880–E888) and the use
of gastroprotective agents (proton pump inhibitors, histamine
H2-receptor antagonists, and cytoprotectant agents), cortico-
steroids, estrogen, and non-steroidal anti-inflammatory drugs
(NSAIDs).
We examined whether patients had received osteoporosis
therapy during the baseline period, within 90 days post-frac-
ture, and within 1 year post-fracture. Patients who had re-
ceived baseline therapy were classified into two groups ac-
cording to whether the days’ supply of medication overlapped
the index date (currently treated) or did not overlap the index
date (not currently treated). All forms of osteoporosis therapy,
oral and parenteral, were considered in the study and included
the bisphosphonates (alendronate, risedronate, ibandronate,
zoledronic acid), calcitonin, denosumab, raloxifene, and
teriparatide.
Dispensed prescriptions for all types of osteoporosis ther-
apy were used to calculate medication possession ratio
(MPR), namely, the proportion of days covered by dispensed
medications. For the post-fracture period, the MPR was cal-
culated as total days’ supply/365. If the total days’ supply
exceeded 365 days, it was truncated to 365 days, yielding a
maximum MPR of 1.0. The MPR for pre-index date therapy
during the baseline period was calculated as the total
days’ supply/730. We defined adherence to therapy as
an MPR ≥0.80.
Statistical analysis
Baseline patient characteristics (including demographic and
clinical parameters) were summarized and described overall
and by index fracture group (vertebral, hip, non-hip/non-ver-
tebral, and multiple fractures). Continuous variables were
summarized by means and standard deviations (SDs), overall
and by fracture group; comparisons were made using F-tests
or Kruskal-Wallis tests where appropriate. Categorical vari-
ables were summarized by the number and percentage of
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patients, overall and by fracture group; comparisons were
made using χ2 tests. A statistical significance level of 5 %
was used for all aforementioned analyses.
Multivariable logistic regression was used to identify the
association between 1-year treatment status (treated vs. not
treated within 1 year post-fracture) and patients’ baseline
treatment status (not treated vs. previously/currently treated)
among index fracture groups, adjusted for baseline patient
characteristics. Interactions between the baseline treatment
status and index fracture group were considered to estimate
differential effects on 1-year treatment status among different
treatment-fracture combinations. Using stepwise (forward and
backward) variable selection with a tuning significance of
20 %, potentially important baseline patient characteristics
were selected from a list of candidate covariates possibly
associated with post-fracture treatment status. The covariates
included age groups, health plan types, Charlson comorbidity
index score, use of concomitant medications, and comorbid
conditions, as listed in Online Resource Table S1. Only
13,380 (28.4 %) patients had a bone mineral density assess-
ment, and the results were not available from the database;
thus, bone mineral density was not used as an inclusion
criterion or included in the model. The final model included
the key predictors (baseline treatment status, index fracture










Age at index date, mean (SD) 63.4 (9.8) 66.8 (10.2) 71.3 (9.6) 61.6 (9.0) 67.8 (10.4)
50–59 years, n (%) 20,931 (44.4) 2,469 (31.5) 610 (16.9) 17,451 (50.7) 401 (29.9)
60–69 years, n (%) 12,446 (26.4) 1,901 (24.3) 657 (18.3) 9,612 (27.9) 276 (20.6)
70–79 years, n (%) 10,515 (22.3) 2,563 (32.7) 1,651 (45.9) 5,827 (16.9) 474 (35.3)
≥80 years, n (%) 3,279 (7.0) 901 (11.5) 681 (18.9) 1,506 (4.4) 191 (14.2)
Insurance type, n (%)
HMO 9,411 (20.0) 1,739 (22.2) 926 (25.7) 6,442 (18.7) 304 (22.7)
POS 21,611 (45.8) 2,952 (37.7) 897 (24.9) 17,311 (50.3) 451 (33.6)
PPO 4,292 (9.1) 787 (10.0) 429 (11.9) 2,930 (8.5) 146 (10.9)
Other 11,857 (25.1) 2,356 (30.1) 1,347 (37.4) 7,713 (22.4) 441 (32.9)
Prior osteoporosis diagnosis, n (%) 9,168 (19.4) 2,230 (28.5) 745 (20.7) 5,877 (17.1) 316 (23.5)
BMD assessment performeda, n (%) 13,380 (28.4) 2,346 (29.9) 731 (20.3) 9,976 (29.0) 327 (24.2)
History of falls of any type resulting in medical services, n (%) 3,470 (7.4) 587 (7.5) 313 (8.7) 2,470 (7.2) 100 (7.5)
Baseline osteoporosis medication, n (%) 9,522 (20.2) 2,171 (27.7) 727 (20.2) 6,291 (18.3) 333 (24.8)
Currently treatedb, n (%) 4,936 (10.5) 1,181 (15.1) 338 (9.4) 3,243 (9.4) 174 (13.0)
CCI score, mean (SD) 1.0 (1.5) 1.3 (1.7) 1.5 (1.8) 0.9 (1.4) 1.2 (1.7)
Key comorbid conditions, n (%)
Osteopenia 8,803 (18.7) 1,600 (20.4) 506 (14.1) 6,471 (18.8) 226 (16.8)
Arthritis 24,992 (53.0) 4,808 (61.4) 2,151 (59.8) 17,293 (50.3) 740 (55.1)
Myocardial infarction 1,242 (2.6) 319 (4.1) 168 (4.7) 710 (2.1) 45 (3.4)
Cerebrovascular disease 5,113 (10.8) 1,162 (14.8) 731 (20.3) 3,017 (8.8) 203 (15.1)
Chronic pulmonary disease 10,118 (21.4) 2,124 (27.1) 857 (23.8) 6,853 (19.9) 284 (21.2)
Hypothyroidism 9,870 (20.9) 1,874 (23.9) 747 (20.8) 6,972 (20.3) 277 (20.6)
Diabetes 8,353 (17.7) 1,466 (18.7) 757 (21.0) 5,893 (17.1) 237 (17.7)
Obesity 3,463 (7.3) 554 (7.1) 177 (4.9) 2,664 (7.7) 68 (5.1)
Concomitant medication use, n (%)
Gastroprotective agent 11,509 (24.4) 2,291 (29.2) 988 (27.5) 7,911 (23.0) 319 (23.8)
NSAID 17,384 (36.9) 3,240 (41.4) 1,270 (35.3) 12,438 (36.2) 436 (32.5)
Glucocorticoid 12,896 (27.3) 2,581 (32.9) 839 (23.3) 9,152 (26.6) 324 (24.1)
Estrogen 8,479 (18.0) 1,467 (18.7) 422 (11.7) 6,394 (18.6) 196 (14.6)
BMD bone mineral density, CCI Charlson comorbidity index, HMO health maintenance organization, NSAID non-steroidal anti-inflammatory drug
a BMD results were not available from the database
b Receiving prescribed treatment at index date
Osteoporos Int (2014) 25:2777–2786 2779
group, and their interaction) and the selected factors. The
associations with the 1-year treatment status were quantified
in terms of odds ratios (ORs) with corresponding 95 % con-
fidence intervals (CIs). All analyses were conducted using
SAS software, version 9.3 (SAS Institute, Cary, NC).
Results
A total of 47,171 women were eligible for inclusion in the
analyses; patient selection is depicted in Online Resource
Figure S1. Of these women, 7,834 (17 %) experienced verte-
bral fracture, 3,599 (8 %) hip fracture, 34,396 (73 %) non-hip/
non-vertebral fracture, and 1,342 (3 %) had fractures at mul-
tiple sites. The mean (SD) age at index fracture was 63 (10)
years; 9,168 (19 %) patients had a prior recorded diagnosis of
osteoporosis, and 9,522 (20 %) had received osteoporosis
medication at some point during baseline, including 4,936
(11 %) who were receiving osteoporosis therapy at the time
of fracture (currently treated; Table 1). Conversely, 33,870
(72 %) women had neither an osteoporosis diagnosis nor
osteoporosis therapy during the baseline period. Women with
hip fracture tended to be older and had a slightly higher mean
Charlson comorbidity index score as compared with women
in the other fracture groups (Table 1). A higher proportion of
women with vertebral fracture had a diagnosis of osteoporosis
or osteopenia than those in other fracture groups.
Figure 1 depicts the proportion of women who received
osteoporosis therapy within 90 days and 1 year post-fracture,
overall and according to prior (baseline period) osteoporosis
therapy. A total of 8,445 (18 %) received medication within
90 days post-fracture; most of these women (6,656 [79 %])
had also received osteoporosis therapy during the baseline
period. A total of 10,826 (23 %) women received medication
within 1 year post-fracture, of which 68 % had received
osteoporosis medication during baseline.
Table 2 describes demographic and baseline characteristics
for women according to whether they received osteoporosis
therapy within 90 days or 1 year post-fracture. Patients who
received therapy post-fracture tended to be older than patients
who did not, and they were more likely to have vertebral
fracture, a prior osteoporosis diagnosis, and baseline osteopo-
rosis therapy and to be adherent to baseline therapy; they were
less likely to be obese.
Results of regression analyses supported these findings
(Table 3). The adjusted odds ratio (OR) of receiving therapy
within 1 year post-fracture for women with baseline osteoporo-
sis therapy versus no baseline osteoporosis therapy were signif-
icantly greater for women with vertebral fracture (OR 12.7,
95 % CI 11.2–14.5), hip fracture (OR 15.2, 12.5–18.7), non-
hip/non-vertebral fracture (OR 34.4, 31.7–37.3), or multiple
fractures (OR 18.1, 13.1–25.0). The odds of receiving medica-
tion prescribed for osteoporosis within 1 year post-fracture were
significantly greater for women 60 years of age and older as
compared with those between the ages of 50 and 59 (Table 3).
Likewise, the odds of therapy post-fracture were significantly
greater for women who had a baseline diagnosis of osteoporosis
or osteopenia. As compared with those who had vertebral
fracture, patients with hip, non-vertebral/non-hip, or multiple
fractures had significantly lower odds of receiving therapy with-
in 1 year post-fracture. Obese patients and those with arthritis,
cardiovascular disease, or hypertension also had significantly
lower odds of receiving therapy.
Fig. 1 Percentage of women
prescribed with osteoporosis
medication within 90 days and
within 1 year post-fracture. Prior
treatment was that dispensed
during the baseline period; current
treatment overlapped the index
date. OP osteoporosis, Script
prescription
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Table 2 Characteristics of women according to osteoporosis therapy dispensed during 1 year post-fracture
Characteristic Osteoporosis therapy dispensed
within 90 days post-fracture
Osteoporosis therapy dispensed
within 1 year post-fracture
Yes (n=8,445) No (n=38,726) Yes (n=10,826) No (n=36,345)
Age at index date, mean (SD) 66.5 (9.6) 62.7 (9.7) 66.2 (9.6) 62.5 (9.7)
50–59 years 2,481 (29.4) 18,450 (47.6) 3,338 (30.8) 17,593 (48.4)
60–69 years 2,579 (30.5) 9,867 (25.5) 3,248 (30.0) 9,198 (25.3)
70–79 years 2,496 (29.6) 8,019 (20.7) 3,181 (29.4) 7,334 (20.2)
≥80 years 889 (10.5) 2,390 (6.2) 1,059 (9.8) 2,220 (6.1)
Insurance type
HMO 1,495 (17.7) 7,916 (20.4) 2,069 (19.1) 7,342 (20.2)
POS 3,445 (40.8) 18,166 (46.9) 4,427 (40.9) 17,184 (47.3)
PPO 943 (11.2) 3,349 (8.6) 1,170 (10.8) 3,122 (8.6)
Other 2,562 (30.3) 9,295 (24.0) 3,160 (29.2) 8,697 (23.9)
Prior osteoporosis diagnosis 4,212 (49.9) 4,956 (12.8) 4,921 (45.5) 4,247 (11.7)
BMD assessment performeda 4,426 (52.4) 8,954 (23.1) 5,193 (48.0) 8,187 (22.5)
History of falls of any type resulting in medical services 634 (7.5) 2,836 (7.3) 819 (7.6) 2,651 (7.3)
Baseline osteoporosis medication 6,656 (78.8) 2,866 (7.4) 7,364 (68.0) 2,158 (5.9)
Pre-index MPR, mean (SD) 0.57 (0.30) 0.26 (0.22) 0.54 (0.30) 0.24 (0.22)
Adherent patientsb, n (% of those on baseline Rx) 2,101 (31.6) 67 (2.3) 2,122 (28.8) 46 (2.1)
Currently treatedc 4,936 (58.4) n/a 4,936 (45.6) n/a
Not currently treated 1,720 (20.4) 2,866 (7.4) 2,428 (22.4) 2,158 (5.9)
Index fracture group
Vertebral 2,400 (28.4) 5,434 (14.0) 2,936 (27.1) 4,898 (13.5)
Hip 663 (7.9) 2,936 (7.6) 898 (8.3) 2,701 (7.4)
Non-hip/non-vertebral 5,095 (60.3) 29,301 (75.7) 6,604 (61.0) 27,792 (76.5)
Multiple 287 (3.4) 1,055 (2.7) 388 (3.6) 954 (2.6)
CCI score, mean (SD) 1.1 (1.5) 1.0 (1.5) 1.1 (1.5) 1.0 (1.6)
Key comorbid conditions
Osteopenia 3,016 (35.7) 5,787 (14.9) 3,622 (33.5) 5,181 (14.3)
Arthritis 4,867 (57.6) 20,125 (52.0) 6,218 (57.4) 18,774 (51.7)
Musculoskeletal pain 4,120 (48.8) 16,133 (41.7) 5,248 (48.5) 15,005 (41.3)
Cardiovascular disease 1,227 (14.5) 5,356 (13.8) 1,597 (14.8) 4,986 (13.7)
Myocardial infarction 203 (2.4) 1,039 (2.7) 264 (2.4) 978 (2.7)
Hypertension 4,733 (56.0) 20,881 (53.9) 6,060 (56.0) 19,554 (53.8)
Cerebrovascular disease 1,082 (12.8) 4,031 (10.4) 1,383 (12.8) 3,730 (10.3)
Chronic pulmonary disease 1,949 (23.1) 8,169 (21.1) 2,537 (23.4) 7,581 (20.9)
Respiratory disease 3,383 (40.1) 14,453 (37.3) 4,324 (39.9) 13,512 (37.2)
Hypothyroidism 1,967 (23.3) 7,903 (20.4) 2,517 (23.2) 7,353 (20.2)
Hyperthyroidism 201 (2.4) 818 (2.1) 271 (2.5) 748 (2.1)
Diabetes 1,235 14.6) 7,118 (18.4) 1,624 (15.0) 6,729 (18.5)
Obesity 354 (4.2) 3,109 (8.0) 467 (4.3) 2,996 (8.2)
Alzheimer’s disease, dementia, depression, anxiety, sleep disorder 2,551 (30.2) 12,233 (31.6) 3,360 (31.0) 11,424 (31.4)
Bulimia nervosa, anorexia nervosa, or anorexia 588 (7.0) 2,082 (5.4) 739 (6.8) 1,931 (5.3)
Kidney disease 561 (6.6) 2,380 (6.1) 699 (6.5) 2,242 (6.2)
Vitamin D deficiency 309 (3.7) 1,036 (2.7) 378 (3.5) 967 (2.7)
Concomitant medication use
Gastroprotective agent 2,541 (30.1) 8,968 (23.2) 3,194 (29.5) 8,315 (22.9)
NSAIDs 3,552 (42.1) 13,832 (35.7) 4,534 (41.9) 12,850 (35.4)
Glucocorticoids 2,725 (32.3) 10,171 (26.3) 3,451 (31.9) 9,445 (26.0)
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Table 2 (continued)
Characteristic Osteoporosis therapy dispensed
within 90 days post-fracture
Osteoporosis therapy dispensed
within 1 year post-fracture
Yes (n=8,445) No (n=38,726) Yes (n=10,826) No (n=36,345)
Estrogen 1,538 (18.2) 6,941 (17.9) 1,996 (18.4) 6,483 (17.8)
Data are n (column %) unless otherwise indicated
BMD bone mineral density, CCI Charlson comorbidity index, HMO health maintenance organization, MPR medication possession ratio, n/a not
applicable, NSAID non-steroidal anti-inflammatory drug, POS point of service, PPO preferred provider organization, Rx therapy
a BMD results were not available from the database
bAdherence defined as MPR ≥0.80
c Current treatment at index date
Table 3 Multivariable logistic regression on association between post-fracture treatment (within 1 year) and pre-fracture patient characteristics
Variables Adjusted Odds ratio 95 % CI P value
Index fracture site <0.001
Hip fracture only vs. vertebral fracture only 0.53 (0.47–0.60)
Non-hip/non-vertebral fracture only vs. vertebral fracture only 0.29 (0.26–0.31)
Fractures at multiple sites vs. vertebral fracture only 0.56 (0.46–0.68)
Treatment vs. non-treatment before the index fracture <0.001
Among women with vertebral fracture only 12.73 (11.17–14.50)
Among women with hip fracture only 15.24 (12.45–18.66)
Among women with non-hip/non-vertebral fracture only 34.35 (31.67–37.26)
Among women with fracture at multiple sites 18.09 (13.10–24.99)
Age group <0.001
60–69 vs. 50–59 1.31 (1.22–1.42)
70–79 vs. 50–59 1.68 (1.55–1.82)
80 or above vs. 50–59 1.37 (1.22–1.55)
Pre-fracture concomitant medication use
Gastroprotective agents 1.05 (0.98–1.13) 0.14
NSAIDs 1.15 (1.08–1.22) <0.001
Glucocorticoid 1.16 (1.08–1.24) <0.001
Estrogen 1.08 (1.00–1.17) 0.038
Pre-fracture diagnosis of comorbid conditions
Osteoporosis 1.55 (1.44–1.66) <0.001
Osteopenia 1.41 (1.32–1.51) <0.001
Arthritis 0.93 (0.87–0.99) 0.023
Musculoskeletal pain 0.95 (0.89–1.01) 0.099
Respiratory disease 0.93 (0.87–0.99) 0.024
Hyperthyroidism 1.15 (0.95–1.40) 0.14
Alzheimer’s disease, dementia, depression, anxiety, sleep disorder 0.96 (0.90–1.02) 0.16
Cardiovascular disease 0.89 (0.81–0.96) 0.006
Kidney disease 0.88 (0.78–1.00) 0.044
Obesity 0.70 (0.62–0.80) <0.001
Hypertension 0.89 (0.83–0.95) <0.001
Vitamin D deficiency 0.84 (0.71–1.00) 0.052
Bulimia nervosa, anorexia nervosa, or anorexia 0.80 (0.58–1.11) 0.18
CI confidence interval, NSAID non-steroidal anti-inflammatory drug
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Adherence to therapy during both baseline and post-
fracture was significantly higher for women who had a base-
line diagnosis of osteoporosis than for those who did not
(Table 4). Women with osteoporosis diagnosis represented
slightly over half (57 %) of patients treated during baseline
and slightly under half (46 %) of those treated post-fracture.
Among the women who received therapy during the baseline
period but not within 1 year post-fracture, adherence to base-
line therapy was very low (2 % of patients adherent during
baseline) as compared with those who received both baseline
and post-fracture therapy (29 % adherent during baseline)
(Table 2).
Table 5 summarizes patient adherence to baseline and post-
fracture therapy according to fracture group and osteoporosis
medication class. Approximately 75 % of patients who were
prescribed with osteoporosis therapy during either baseline or
post-fracture received a bisphosphonate, and another 7 %
were switched between bisphosphonate and non-
bisphosphonate therapy. There were several significant differ-
ences among the fracture groups in patient adherence to
therapy during baseline and post-fracture. Women with hip
fracture had the lowest adherence to bisphosphonates and
overall to therapy during baseline and post-fracture, with only
21 % of patients adherent to therapy post-fracture. Women
with multiple fractures also showed poor adherence during the
post-fracture year, with 23% adherent overall in contrast to 29
and 32 % of patients with vertebral and non-hip/non-vertebral
fractures, respectively (Table 5).
Discussion
This large retrospective study found that only 18 % of the
women included in the analysis received osteoporosis therapy
within 90 days post-fracture, and less than a quarter overall
(23 %) received therapy within the first year post-fracture.
These findings indicate that older women frequently do not
receive pharmacologic therapy for osteoporosis after their first
fracture. Lack of therapy was especially pronounced for wom-
en with non-hip/non-vertebral fracture, of whom only 19 %
received therapy within 1 year post-fracture, followed in fre-
quency by those with hip fracture (25 %). Patients who had a
prior diagnosis of osteoporosis or osteopenia had significantly
higher odds of receiving therapy post-fracture. Moreover,
baseline medication use was a good predictor of post-
fracture medication use, as 77 % of women who had received
prior osteoporosis therapy during baseline subsequently re-
ceived therapy at or after their first fracture.
Other studies have reported low rates of pharmacologic
therapy after osteoporotic fracture. In Canada, Leslie et al.
[15] found that therapy was initiated in the year after fracture
for only 10 % of patients in 2005/2006, falling to 6 % in
2007/2008. The corresponding figure for our study was 9% of
patients without prior baseline therapy who initiated osteopo-
rosis therapy within 1 year after fracture. Moreover, because
more than half of the 18 % of women who initiated therapy
within 90 days post-fracture were already receiving current
therapy, essentially only 7–8 % of women started therapy
within 90 days post-fracture. This number increased to include
only another 5 % of women at 1 year post-fracture (namely,
from 18 to 23 % overall). In an earlier systematic review of 37
studies [20], post-fracture therapy rates exceeded 10% in only
six studies. Other studies report low rates of post-fracture
therapy even for patients with hip fracture and those hospital-
ized for fracture [16, 17, 19]. Our findings highlight the
importance of assessing older women with non-hip/non-ver-
tebral fractures as these women represented the majority of
our study population (73 %) and had the lowest rates of
osteoporosis baseline therapy, osteoporosis diagnosis, and
post-fracture therapy of the four fracture groups.
Table 4 Baseline and post-fracture osteoporosis treatment status and adherence, overall and by baseline osteoporosis diagnosis
All women
(n=47,171)
Osteoporosis diagnosis at baseline P valuea
Yes No
Baseline period osteoporosis therapy
Users, n (%) 9,522 (20.2) 5,389 (56.6) 4,133 (43.4)
Pre-index MPR, mean (SD) 0.48 (0.31) 0.49 (0.31) 0.46 (0.31) <0.001
Adherent patientsb, n (% of users) 2,168 (22.8) 1,269 (23.5) 899 (21.8) 0.038
Post-fracture osteoporosis therapy
Users, n (%) 10,826 (23.0) 4,921 (45.5) 5,905 (54.5)
Post-fracture MPR, mean (SD) 0.55 (0.31) 0.60 (0.30) 0.51 (0.31) <0.001
Adherent patientsb, n (% of users) 3,227 (29.8) 1,739 (35.3) 1,488 (25.2) <0.001
MPR medication possession ratio
a Categorical variables compared with χ2 test, continuous variables with t test (yes vs. no diagnosis at baseline)
b Adherence defined as MPR ≥0.80
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Several reasons have been proposed for the under-prescribing
of osteoporosis therapies after fracture. In some settings, there is
lack of coordination of care: For example, orthopedic surgeons
may not initiate medical therapy or communicate with primary
care physicians regarding their patients with osteoporotic frac-
tures [28]. Another potential reason is patient or physician con-
cerns about the tolerability of therapy; limited data suggest
patient concerns [29] and that some physiciansmay not prescribe
treatment because of concerns about adverse effects [28]. Re-
ported strategies shown to improve the post-fracture treatment
gap include multidisciplinary interventions to educate and moti-
vate both patients and their health care providers [30–32]. Work
by Beaton et al. [33] has identified the importance of patient-
perceived need for therapy in predicting the initiation of therapy













Baseline osteoporosis treatment overall
Users, n (%) 9,522 (20.2) 2,171 (27.7) 727 (20.2) 6,291 (18.3) 333 (24.8)
Pre-index MPR, mean (SD) 0.48 (0.31) 0.48 (0.32) 0.46 (0.31) 0.47 (0.31) 0.51 (0.31) 0.075
Adherent patients, n (% of users) 2,168 (22.8) 532 (24.5) 145 (19.9) 1413 (22.5) 78 (23.4) 0.059
Bisphosphonate use only
Users, n (%) 7,286 (76.5) 1,607 (74.0) 532 (73.2) 4,875 (77.5) 272 (81.7)
Pre-index MPR, mean (SD) 0.47 (0.31) 0.48 (0.32) 0.44 (0.31) 0.46 (0.31) 0.49 (0.31) 0.031
Adherent patientsa, n (% of users) 1,567 (21.5) 377 (23.5) 91 (17.1) 1,040 (21.3) 59 (21.7) 0.020
Non-bisphosphonate use only
Users, n (%) 1,538 (16.2) 361 (16.6) 136 (18.7) 1,002 (15.9) 39 (11.7)
Pre-index MPR, mean (SD) 0.47 (0.32) 0.42 (0.33) 0.47 (0.33) 0.48 (0.31) 0.53 (0.32) 0.008
Adherent patients, n (% of users) 354 (23.0) 72 (19.9) 35 (25.7) 237 (23.7) 10 (25.6) 0.41
Bisphosphonate and non-bisphosphonate useb
Users, n (%) 698 (7.3) 203 (9.4) 59 (8.1) 414 (6.6) 22 (6.6)
Pre-index MPR, mean (SD) 0.61 (0.29) 0.62 (0.30) 0.56 (0.29) 0.60 (0.28) 0.66 (0.27) 0.47
Adherent patients, n (% of users) 247 (35.4) 83 (40.9) 19 (32.2) 136 (32.9) 9 (40.9) 0.22











Post-fracture osteoporosis treatment overall
Users, n (%) 10,826 (23.0) 2,936 (37.5) 898 (25.0) 6,604 (19.2) 388 (28.9)
Post-fracture MPR, mean (SD) 0.55 (0.31) 0.55 (0.31) 0.51 (0.30) 0.56 (0.31) 0.51 (0.29) <0.001
Adherent patients, n (% of users) 3,227 (29.8) 864 (29.4) 190 (21.2) 2083 (31.5) 90 (23.2) <0.001
Bisphosphonate use only
Users, n (%) 8,243 (76.1) 1,979 (67.4) 692 (77.1) 5,276 (79.9) 296 (76.3)
Post-fracture MPR, mean (SD) 0.54 (0.30) 0.55 (0.31) 0.49 (0.29) 0.55 (0.31) 0.51 (0.29) <0.001
Adherent patientsa, n (% of users) 2,364 (28.7) 577 (29.2) 131 (18.9) 1,592 (30.2) 64 (21.6) <0.001
Non-bisphosphonate use only
Users, n (%) 1,782 (16.5) 594 (20.2) 141 (15.7) 989 (15.0) 58 (14.9)
Post-fracture MPR, mean (SD) 0.53 (0.32) 0.45 (0.32) 0.47 (0.30) 0.57 (0.31) 0.46 (0.32) <0.001
Adherent patients, n (% of users) 501 (28.1) 126 (21.2) 29 (20.6) 333 (33.7) 13 (22.4) <0.001
Bisphosphonate and non-bisphosphonate useb
Users, n (%) 801 (7.4) 363 (12.4) 65 (7.2) 339 (5.1) 34 (8.8)
Post-fracture MPR, mean (SD) 0.69 (0.26) 0.69 (0.26) 0.69 (0.26) 0.70 (0.26) 0.62 (0.26) 0.45
Adherent patients, n (% of users) 362 (45.2) 161 (44.4) 30 (20.6) 158 (46.6) 13 (22.4) 0.79
MPR medication possession ratio
a Adherence defined as MPR ≥0.80
b Patients were switched between bisphosphonate and non-bisphosphonate (not concomitant use)
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after fracture. Further education regarding osteoporosis manage-
ment including fracture liaison services programs or adherence
programs may lead to improved outcomes and lower health care
resource use and costs [34–36].
A strength of this study is the large patient population and
the fact that we followed women for 3 consecutive years
including 1 year post-fracture. Moreover, the results depict
current treatment practices in the USA, drawn from real-life
patient data recorded from 2003 to mid-2012. We did not
investigate the reasons for under-treatment in the present study
but instead sought to characterize women who did not receive
osteoporosis therapy post-fracture.
A limitation of our analyses, as for all studies using admin-
istrative claims data, is that inaccuracies associated with coding
errors could lead to misclassification of patients. Moreover, the
analyses relied on prescription claims as a proxy for medication
use. While this method gives a clear indication of dispensing
patterns, the data on adherence are less reliable because we had
no way to track whether women actually took the medication as
prescribed. Moreover, the dataset does not include a record of
prescriptions that were not filled; therefore, our findings could
represent a combination of under-prescribing by health care
providers as well as patient non-compliance with initiating
prescribed therapy. It is not possible from the database to
identify with certainty the specialty of the treating physicians.
In addition, it is possible that falls were under-reported and that
we included some fractures that were not osteoporotic, although
we restricted the patient population to women 50 years of age
and older and excluded fractures that are not considered oste-
oporotic by expert consensus [37]. Finally, we cannot rule out
unrecognized confounding factors subjecting our results to bias.
The post-fracture treatment gap is a well-recognized prob-
lem for patients with osteoporotic fracture, exposing them to
increased risk of subsequent fracture. The results of this study
indicate that lack of post-fracture pharmacotherapy remains a
problem among older women with osteoporotic fracture in the
US and constitutes an important unmet need for preventing
subsequent fracture. Our findings highlight the need for phy-
sician education about osteoporosis risk assessment and for
increased patient education and involvement in their care to
help reduce the risk and occurrence of osteoporotic fractures
and overall health care burden as a result.
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